9月5日的资金流向数据方面，主力资金净流入362.73万元，占总成交额6.8%，游资资金净流出37.59万 元，占总成交额0.7%，散户资金净流出325.14万元，占总成交额6.1%。 近5日资金流向一览见下表： 证券之星消息，截至2025年9月5日收盘，中 关 村(000931)报收于5.32元，上涨0.76%，换手率1.35%， 成交量10.11万手，成交额5332.84万元。 | 指标 | 中关村 | 化学制药行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 40.07亿元 | 163.21亿元 | 114 146 | | 净资产 | 18.52亿元 | 48.81亿元 | 89 146 | | 净利润 | 3880.89万元 | 2.25亿元 | 85 146 | | 市盈率(动) | 51.62 | 98.18 | 74 146 | | 市净率 | 2.46 | 5.67 | 53 146 | | 毛利率 | 60.8% | 49.61% | 46 146 | | 净利率 | 3.61% | -0.49% | 95 146 | | ROE | 2.41% ...

格隆汇9月5日丨富祥药业(300497.SZ)于近期投资者关系活动表示，公司三氮唑新工艺他唑巴坦产品顺 利完成下游客户合格供应商备案，产品产能有望释放，将不仅能够降低他唑巴坦产品生产成本，同时还 能提高产品售价及市场竞争力。 ...

（文章来源：证券日报） 证券日报网讯 9月5日晚间，药石科技发布公告称，公司第四届董事会第十次会议审议通过了《关于调 整2025年度日常关联交易预计的议案》。 ...

诚达药业（301201）(301201.SZ)发布公告，持有公司股份1100.69万股(占公司剔除回购专户股份数后总 股本比例7.27%)的股东深圳前海晟泰投资企业(有限合伙)计划在公告披露之日起15个交易日后的3个月 内(2025年9月29日至2025年12月28日)以集中竞价或大宗交易方式减持公司股份不超过1100.69万股(占公 司剔除回购专户股份数后总股本比例7.27%)。 ...

人民财讯9月5日电，信立泰（002294）9月5日晚间公告，近日，公司收到国家药监局核准签发的恩那度 司他片(恩那罗)药品注册证书，其用于治疗透析(包括血液透析和腹膜透析)慢性肾脏病(CKD)患者的贫 血适应症获批。 恩那罗是国内上市的新一代缺氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)药物，2023年已获批用于非透 析的成人慢性肾脏病(CKD)患者的贫血治疗，并于同年被纳入国家医保目录；此次获批的适应症为治疗 透析CKD患者的贫血(统称"肾性贫血")。 ...

Core Viewpoint - Fuxiang Pharmaceutical is experiencing a growth in its mid-year performance compared to last year, but it remains in a loss position. The company plans to improve its net profit through various products and strategies [2]. Group 1: Business Performance and Strategies - The company aims to enhance its pharmaceutical business by increasing the selling price of key intermediates and expanding production capacity for various products, which will improve gross margins and competitiveness [2]. - In the new energy sector, Fuxiang's lithium battery electrolyte additive products are performing well in terms of shipment volume and cost control, with prices at historical lows, indicating potential for profit growth as the industry recovers [2]. - The synthetic biology sector is being developed with a focus on microbial protein, with a new food raw material application already accepted for review by the National Health Commission, aiming for approval and market launch in the second half of the year [2][4]. Group 2: Microbial Protein Business Advantages - Fuxiang Pharmaceutical is a pioneer in the domestic microbial protein industry, with significant production capacity and proprietary technology, including patents in multiple countries [3]. - The company has achieved international advanced levels in key technologies for microbial protein production and has received various quality certifications for its products [3]. - Collaborations with academic institutions are in place to foster innovation across the entire industry chain, emphasizing green production and cost efficiency [3]. Group 3: Future Plans for Synthetic Biology - The company plans to obtain necessary approvals for its new protein products and enhance market presence through brand building and international expansion [4]. - Focus will be on accelerating the industrialization of new protein products and recruiting talent to build a high-performance team [4]. - Strategic partnerships have been established to advance product development and market promotion, with a strong outlook for amino acid water-soluble fertilizers [4].

Core Viewpoint - The company, Xinlitai (002294.SZ), has received a notice of acceptance from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0139, which is intended for the treatment of hyperlipidemia [1] Company Summary - The drug SAL0139 is developed by the company and possesses independent intellectual property rights [1] - The application submitted by the company is specifically for conducting clinical trials of SAL0139 for hyperlipidemia treatment [1]

Financial Performance - The company reported an increase in mid-year performance compared to last year, but remains in a loss state [2] - Future strategies will focus on improving net profit through various products and avenues [2] Pharmaceutical Manufacturing - The decline in raw material prices for 6-APA and the recovery in prices for the key intermediate 4-AA will enhance the gross margin of the pharmaceutical business [3] - Successful completion of supplier qualification for the new process product, Tazobactam, is expected to reduce production costs and improve market competitiveness [3] - Expansion of Piperacillin production capacity is underway, with significant market demand for combination formulations [3] - New compound formulations are being launched, which will drive demand for related products [3] New Energy Business - The company leads in the industry for lithium battery electrolyte additives in terms of shipment volume and cost control [3] - Current prices for these additives are at historical lows, with limited room for further decline; a price rebound could significantly enhance profits [3] Synthetic Biology - The company is a pioneer in microbial protein production, with significant advancements in core strains, production technology, and market access [4][5] - The registration application for the new protein as a food ingredient has been accepted, with expectations for approval in the second half of the year [4][9] - The company is constructing a project with an annual capacity of 200,000 tons of microbial protein, aiming for a production scale of 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer [5][15] Quality and Certification - The new protein has received multiple international certifications, including HALAL and KOSHER, and has passed various food safety management system certifications [6] - The company has developed proprietary strains and achieved international advanced levels in production technology [5][6] Market Expansion and Collaboration - Strategic partnerships have been established with various companies in the microbial protein sector, enhancing market penetration [11] - The company plans to build an open commercial transformation platform to accelerate product commercialization and brand development [10] Product Development - The new protein can be applied in various sectors, including plant-based meat alternatives, protein drinks, and health products [12] - The company is actively developing new applications and has created several product samples for market introduction [12] Environmental and Regulatory Compliance - The company’s production processes aim for zero emissions and align with national agricultural reduction goals [7][14] - The amino acid water-soluble fertilizer is positioned to meet growing market demands due to regulatory support for green products [15]

华银电力：股东拟减持不超过1%公司股份 9月5日晚，华银电力（600744）发布公告称，公司股东湖南能源集团有限公司（简称"湖南能源"）拟通 过集中竞价方式，减持公司股份合计不超过2031.12万股，不超过公司总股本的1%。 资料显示，华银电力成立于1993年3月，主营业务是火力发电业务，同时经营水电、风电、太阳能业务 以及电力销售业务。 所属行业：公用事业–电力–火电 安凯客车：8月客车销量773辆 9月5日晚，安凯客车（000868）发布公告称，公司8月客车产量为1012辆，同比增长68.06%；销量为 773辆，同比增长46.95%。其中，大型客车产量同比增长214.00%，销量同比增长164.26%。 资料显示，安凯客车成立于1997年7月，主营业务是客车整车及汽车零部件的研发、制造、销售和服务 于一体并坚持自主研发。 所属行业：汽车–商用车–商用载客车 联环药业：法莫替丁注射液获药品注册证书 9月5日晚，联环药业（600513）发布公告称，公司近日收到国家药品监督管理局核准签发的法莫替丁注 射液《药品注册证书》。该药品为化学药品3类，视同通过仿制药质量和疗效一致性评价。 资料显示，联环药业成立于20 ...

Core Viewpoint - JYSW003 project by Tianjin Pharmaceutical Industry Co., Ltd. shows promising efficacy and safety for psoriasis treatment, with ongoing exploratory research [1] Group 1 - The JYSW003 project is an innovative drug initiative commissioned by Tianjin Pharmaceutical's innovation research institute [1] - Preliminary research results indicate significant drug efficacy and superior safety characteristics [1] - The company plans to establish an innovation research institute in 2024 to focus on drug design, discovery, and incubation [1] Group 2 - Current projects in the innovative drug pipeline are in the early exploratory research phase [1] - The company aims to enhance its product pipeline, accelerate diversified development, and concentrate resources on high-value products [1] - The strategy includes continuous project initiation to build product advantages and expand market space for optimized product structure [1]